Avalo Therapeutics AVTX Business Segments — CMC expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:ChemistryManufacturingAndControlExpenses.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's business segments — cmc expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's business segments — CMC expenses?
- Avalo Therapeutics (AVTX) reported business segments — CMC expenses of $4.13M in Q1 2026.
- How has Avalo Therapeutics's business segments — CMC expenses changed year-over-year?
- Avalo Therapeutics's business segments — CMC expenses increased by 108.5% year-over-year, from $1.98M to $4.13M.
- What is the long-term trend for Avalo Therapeutics's business segments — CMC expenses?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — CMC expenses has grown at a 128.2% compound annual growth rate (CAGR), from $1.86M to $9.66M.
- What does business segments — CMC expenses mean?
- Covers Chemistry, Manufacturing, and Controls (CMC) activities required to develop and scale the manufacturing processes for drug candidates. These costs ensure that the drug product is produced consistently and meets quality standards for clinical trials and commercial supply. Effective management of CMC expenses is essential for transitioning from research to scalable drug production.